Leonard S Schleifer Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

Leonard S Schleifer is Bd. Co-Chair, President & CEO of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 466,877 shares of REGN, which is worth approximately $528 Million. The most recent transaction as insider was on May 17, 2024, when has been sold 22,830 shares (Common Stock) at a price of $979.64 per share, resulting in proceeds of $22,365,181. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 467K

0% 3M change

0.2% 12M change

Total Value Held $528 Million

LEONARD S SCHLEIFER Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 17 2024	SELL Open market or private sale	$22,365,181 $979.64 p/Share	22,830 Reduced 4.66%	466,877 Common Stock
May 15 2024	SELL Open market or private sale	$10,766,272 $984.03 p/Share	10,941 Reduced 2.68%	397,259 Common Stock
May 14 2024	SELL Open market or private sale	$24,490,750 $979.63 p/Share	25,000 Reduced 5.77%	408,200 Common Stock
May 13 2024	SELL Payment of exercise price or tax liability	$141,080,710 $976.79 p/Share	144,433 Reduced 25.0%	433,200 Common Stock
May 13 2024	BUY Exercise of conversion of derivative security	$81,212,510 $399.66 p/Share	203,204 Added 26.02%	577,633 Common Stock
Dec 11 2023	SELL Payment of exercise price or tax liability	$10,838,959 $844.09 p/Share	12,841 Reduced 3.32%	374,429 Common Stock
Dec 11 2023	BUY Exercise of conversion of derivative security	-	25,155 Added 6.1%	387,270 Common Stock
Nov 19 2021	SELL Payment of exercise price or tax liability	$234,142,966 $651.96 p/Share	359,137 Reduced 43.53%	465,922 Common Stock
Nov 19 2021	BUY Exercise of conversion of derivative security	$116,955,956 $224.78 p/Share	520,313 Added 44.4%	651,568 Common Stock
Aug 18 2021	SELL Open market or private sale	$130,006,006 $650.03 p/Share	200,000 Reduced 39.62%	304,746 Common Stock
Aug 06 2021	SELL Payment of exercise price or tax liability	$138,861,600 $607.51 p/Share	228,575 Reduced 31.17%	504,746 Common Stock
Aug 06 2021	BUY Exercise of conversion of derivative security	$20,812,000 $52.03 p/Share	400,000 Added 40.15%	596,176 Common Stock

LSS

Leonard S Schleifer

Bd. Co-Chair, President & CEO

Tarrytown, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Value

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN

Account